

## EMERGING COMPANY PROFILE

# NeoPhore: Driving neoantigen production via DNA mismatch repair

BY MARY ROMEO, ASSISTANT EDITOR

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack.

Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune system regards as non-self -- including T cell therapies and cancer vaccines that either target or deliver the newly formed antigens.

NeoPhore Ltd. wants to take a different tack by creating the neoantigens in the patient to make the tumors more visible to the immune system. The company is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of neoantigens to turn “dark” tumors “light” that can be treated with immunotherapies.

“Evidence suggests MMR inhibition will re-program a wholly new, diverse collection of neoantigens and related immune signaling inside patient cancers,” CEO Jeff Roix told BioCentury.

NeoPhore spun out of U.K. cancer company PhoreMost Ltd. in 2017, in collaboration with co-founders Alberto Bardelli and Giovanni Germano at University of Turin, to focus on inhibiting mismatch repair with small molecule inhibitors.

Inhibiting genes in the DNA mismatch repair pathway creates a microsatellite instability state. Studies have shown microsatellite instability creates indels and frameshift mutations; additional research has suggested these produce immunogenic neoantigens, and at least two studies have connected frameshift mutations with checkpoint inhibitor responses in patients (see “[Alt-neoantigens](#)”).

Bardelli and Germano published a *Nature* [study](#) in 2017 that reported inactivation of DNA mismatch repair by knocking out MLH1 in cancer cells increases the tumor mutational load and triggers neoantigen production in cancer cells, which accumulated over time. The researchers found expanded T cell receptor (TCR) repertoires and increased levels of cytotoxic T cells in mouse cancer models.

### NEOPHORE LTD. Cambridge, U.K.

**Technology:** Small molecules targeting DNA mismatch repair to stimulate neoantigen production and immune signaling for combination immunotherapy approaches

**Disease focus:** Cancer

**Clinical status:** Discovery

**Founded:** 2017 by Alberto Bardelli and Giovanni Germano

**University collaborators:** University of Turin

**Corporate partners:** Undisclosed

**Number of employees:** 5

**Funds raised:** £3 million (\$4 million)

**Investors:** Sixth Element Capital LLC

**CEO:** Jeff Roix

**Patents:** None issued

Bardelli’s team demonstrated in preclinical models that mismatch repair inhibition creates neoantigen stimulation, Roix said. “Our founders showed that inhibiting these factors brightens tumors so they can be seen by the immune system.”

Another [study](#) from NeoPhore advisers Bert Vogelstein and Luis Diaz at Johns Hopkins University, published in *Science* in 2017, linked high rates of checkpoint inhibitor responses in patients with mismatch repair deficient (dMMR) cancers to rapid expansion of T cells specific for neoantigens.

The approval of PD-1 inhibitors Keytruda pembrolizumab from Merck & Co. Inc. and later Opdivo nivolumab from Bristol-Myers Squibb Co. validated the company’s strategy, Roix said, that tumors with microsatellite instability are prime targets for immunotherapies. Keytruda is approved for advanced microsatellite instability-high (MSI-H) or dMMR solid tumors regardless of the cancer’s tissue of origin; Opdivo is approved for advanced MSI-H or dMMR metastatic colorectal cancer.

Roix declined to disclose the company's targets but said its "inhibitors are directed against validated classically understood genes in the mismatch repair pathway."

The lead and backup programs are in discovery, and NeoPhore expects to select a candidate in 2020.

NeoPhore is aiming to target cancers that are neoantigen poor, and are therefore not good candidates for immunotherapies. While Roix declined to disclose specific indications, he did say pancreatic and prostate cancer and gliomas are "generally thought to be neoantigen poor."

The strategy could also treat MSI medium or high cancers to enhance immunotherapies, he added. "There may be some cancers that we can push even further."

NeoPhore wants to pair its small molecules with PD-1 checkpoint inhibitors, in particular, and has been seeking partnering opportunities.

"There could be other immune cell effector pathways that could complement" NeoPhore's strategy, he added.

Multiple companies are pursuing neoantigen-based strategies to treat cancer, but most are developing biologics like vaccines or proteins. One company, Nouscom AG, has identified hundreds of neoantigens that frequently occur in patients with MSI-H cancer and plans to deliver them in a single vaccine.

Roix is not aware of any other companies specifically targeting DNA mismatch repair pathways to create neoantigens. "We think we're the first and only mismatch repair company" in the neoantigen space, he said.

Grey Wolf Therapeutics is also developing small molecules to increase tumor visibility to the immune system, but is targeting ERAP1 and ERAP2 -- proteins in the antigen presentation pathway.

Roix estimated the company's £3 million (\$4 million) initial funding from Sixth Element Capital will take it into 2020, during which time NeoPhore will consider pursuing a financing or partnering. **■**

---

#### COMPANIES AND INSTITUTIONS MENTIONED

**Bristol-Myers Squibb Co.** (NYSE:BMJ), New York, N.Y.  
**Grey Wolf Therapeutics**, Oxford, U.K.  
**Johns Hopkins University**, Baltimore, Md.  
**Merck & Co. Inc.** (NYSE:MRK), Kenilworth, N.J.  
**Nouscom AG**, Basel, Switzerland  
**PhoreMost Ltd.**, Cambridge, U.K.  
**University of Turin**, Turin, Italy

---

#### TARGETS

ERAP1 (ARTS1; ERAAP) - Endoplasmic reticulum aminopeptidase 1  
ERAP2 - Endoplasmic reticulum aminopeptidase 2  
MLH1 - DNA mismatch repair protein Mlh1  
PD-1 (PDCD1; CD279) - Programmed cell death 1

## EDITORIAL & RESEARCH

### NEWSROOM:

pressreleases@biocentury.com

SAN CARLOS, CA:

+1 650-595-5333

CHICAGO:

+1 312-755-0798

WASHINGTON, DC:

+1 202-462-9582

UNITED KINGDOM:

+44 (0)1865-512184

*BioCentury Innovations*: Idea to IND

*BioCentury*: Phase I to the Patient

*BioCentury Extra*: Essential News for Biotech and Pharma

**C. Simone Fishburn, Ph.D.**, Editor in Chief

*Editors Emeritus*: Susan Schaeffer (2012-2018);  
Karen Bernstein, Ph.D. (1992-2012)

**Jeff Cranmer**, Executive Editor

**Selina Koch, Ph.D.**, Senior Editor

**Erin McCallister**, Senior Editor & Head: Clinical Development & Market Access

**Steve Usdin**, Senior Editor/Washington & Head: Policy & Regulation

**Karen Tkach Tuzman, Ph.D.**, Associate Editor & Head: Discovery and Preclinical Development

**Jonathan Block, Paul Bonanos, Stephen Hansen, Lauren Martz, Inhua Muijers-Chen, Ph.D., Val Kennedy, Virginia Li, Meredith Durkin Wolfe**, Associate Editors

**Allison Johnson, Ph.D., Winnie Pong, Ph.D.**, Senior Writer

**Mary Romeo**, Assistant Editor

**Elizabeth S. Eaton, Hongjiang Li, Ph.D., Claire Quang, Sandi Wong, Ph.D.**, Staff Writers

**USE OF IMAGES**: Certain Images used in BioCentury Inc.'s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see "Use of Images" found under the "Legal" section on the footer of the homepage at [www.biocentury.com](http://www.biocentury.com).

BioCentury®; Because Real Intelligence is Hard to Find™; BCIQ™; The BioCentury 100™; and The Clear Route to ROI™ are trademarks of BIOCENTURY INC. All contents Copyright © 2019, BIOCENTURY INC. ALL RIGHTS RESERVED. No part of BioCentury's Publications or Website may be copied, reproduced, retransmitted, disseminated, sold, distributed, published, broadcast, circulated, commercially exploited in any form or used to create derivative works without the written consent of BioCentury. Information provided by BioCentury's Publications and Website is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of the information, nor does BioCentury make any warranties of any kind regarding the information. The contents of BioCentury's Publications and Website are not intended as investment, business, tax or legal advice, and BioCentury is not responsible for any investment, business, tax or legal opinions cited therein or for any decision made or action taken in reliance upon such information.

All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Inc.

## CORPORATE, SUBSCRIPTIONS & PRIVACY

BioCentury's mission is to provide value-added business intelligence & analysis for life science companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

BioCentury Inc.  
BioCentury International Inc.

### MAIN OFFICES

1235 Radio Road, Ste. 100  
Redwood City, CA 94065-1217  
+1 650-595-5333; Fax: +1 650-595-5589

### CORPORATE

**Karen Bernstein, Ph.D.**, Co-Founder & Chairman

**David Flores**, Co-Founder, President & CEO

**C. Simone Fishburn, Ph.D.**, Vice President/Editor in Chief

**Adam Gordon**: Vice President/  
Product Management & Marketing

**David Smiling**: Chief Technology Officer

**Bennet Weintraub**: Vice President/  
Administration & CFO

**Eric Pierce**: Publisher

**Susan Morgan**: Senior Director/  
Administration & Human Resources

### BUSINESS DEVELOPMENT

**Joshua Berlin**, Executive Director

**Juli Balestrieri, Kevin Lehnbeuter**, Business Development Managers

### PRODUCT MANAGEMENT & MARKETING

**Greg Monteforte**, Director/  
Marketing & Promotional Services

**Alec Webster**, Product Manager/BCIQ

**Josephine Ascitutto-Bunn**, Marketing Coordinator

### SUBSCRIBER SERVICES

**Tim Tulloch**, Senior Director

**Orlando Abello, Matt Krebs, John Lucas, Michelle Ortega, Ron Rabinowitz**, Account Managers

**Hannibal Adofo, Marilyn Smith**, Subscriber Services

### TECHNOLOGY

**Jenny Nichols**, Director/Publishing

**Lam Lu**, Head/Business Intelligence Group

### BUSINESS SERVICES

**Accounting & Billing**: [finance@biocentury.com](mailto:finance@biocentury.com)

**Conferences**: [conferences@biocentury.com](mailto:conferences@biocentury.com)

**Data Solutions Support**: [support@biocentury.com](mailto:support@biocentury.com)

**Privacy Policy**: [privacy@biocentury.com](mailto:privacy@biocentury.com)

**Reprints/Permissions**:  
[businessservices@biocentury.com](mailto:businessservices@biocentury.com)

### PRIVACY & ADVERTISING

In accordance with its Privacy Policy, BioCentury does NOT sell its customer information or usage data to third parties. BioCentury does NOT sell advertising in the BioCentury, BioCentury Innovations or BioCentury Week in Review publications. BioCentury is pleased to acknowledge its conference partners and sponsors through promotional announcements in its publications. BioCentury MAY accept paid promotional messages from sponsors, which are displayed only on BioCentury's websites and in BioCentury Extra.